Systemic Treatment With Everolimus for the Prevention of MACE After Bare Metal Stent Implantation

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2007 by German Heart Institute.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Novartis
Information provided by:
German Heart Institute
ClinicalTrials.gov Identifier:
NCT00426049
First received: January 23, 2007
Last updated: NA
Last verified: January 2007
History: No changes posted
  Purpose

The purpose of the present study is to provide the first in-human safety and efficacy evaluations of systemic oral anti-proliferative Everolimus therapy compared to placebo in patients treated by bare metal stents for significant coronary artery disease. The aim is to reduce Major Adverse Cardiac Events (MACEs) including death, coronary artery bypass grafting (CABG) to the target vessel, Q-wave and non-Q-wave myocardial infarction, and target lesion revascularization within the first 6 months after intervention. Additionally safety and tolerability of Everolimus at the selected dose in this patient population will be analyzed.


Condition Intervention Phase
Coronary Artery Disease
Coronary Restenosis
Drug: Everolimus
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Monocenter, Double Blinded, Prospective, Randomized Placebo Controlled Study Investigating Prevention of Major Adverse Cardiac Events (MACEs) Within 6 Months by Systemic Treatment With Everolimus After Coronary Intervention With Bare Metal Stents in Patients With Significant Coronary Artery Disease

Resource links provided by NLM:


Further study details as provided by German Heart Institute:

Primary Outcome Measures:
  • Major adverse cardiac events (MACEs)within 6 months

Secondary Outcome Measures:
  • MACEs within 30 days
  • Quantitative angiographic observations within the vessel after 6 months
  • TLR and TVR after 6 months
  • Drug safety and tolerability for 6 months

Estimated Enrollment: 484
Study Start Date: October 2006
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Males or females, aged >18 years.
  2. Patients with coronary artery disease who are scheduled for coronary intervention with bare metal stent placement for treatment of de novo or first restenosis in a native coronary artery.
  3. Target lesion must be in a native coronary vessel of 2.25 – 4.0 mm size.
  4. Target lesion has to be of less than or equal to 25 mm length.
  5. Tandem lesion may be included as long as:

    • overall length is less than or equal to 25 mm
    • tandem lesion will be treated with one stent and counted as one lesion.

Exclusion Criteria:

The following exclusion criteria must not be present at Baseline visit 1 (BL1, Screening visit prior to coronary intervention). If an exclusion criterion occurred afterwards, e.g., during the coronary intervention, the patient must be excluded from the study.

  1. Target lesion has a reference vessel size of less than 2.25 or more than 4.0 mm diameter.
  2. Target lesion is a total occlusion or located at a bifurcation.
  3. Treatment affords implantation of more than one stent per treated lesion.
  4. Target lesion was already treated by brachytherapy.
  5. Target lesion has one or more of the following criteria:

    • Left main lesion
    • Ostial lesion of the RCA
    • Located at less than 2 mm after the origin of the LAD or RCX.

Other protocol defined inclusion/exclusion criteria may apply.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00426049

Contacts
Contact: Eckart Fleck, Professor +49-(0)30-4593 ext 2400 fleck@dhzb.de

Locations
Germany
German Heart Institute Berlin Recruiting
Berlin, Germany, 13353
Principal Investigator: Eckart Fleck, Professor         
Sponsors and Collaborators
German Heart Institute
Novartis
Investigators
Principal Investigator: Eckart Fleck, Professor German Heart Institute Berlin
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00426049     History of Changes
Other Study ID Numbers: CRAD001ADE07
Study First Received: January 23, 2007
Last Updated: January 23, 2007
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by German Heart Institute:
Coronary artery disease
Stents
Immunosuppressive Agents
Coronary restenosis
Safety

Additional relevant MeSH terms:
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Coronary Restenosis
Heart Diseases
Cardiovascular Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Coronary Stenosis
Immunosuppressive Agents
Everolimus
Sirolimus
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions
Antibiotics, Antineoplastic
Antineoplastic Agents
Therapeutic Uses
Antifungal Agents
Anti-Infective Agents
Anti-Bacterial Agents

ClinicalTrials.gov processed this record on July 22, 2014